258 related articles for article (PubMed ID: 30175227)
1. The price of progress: Funding and financing Alzheimer's disease drug development.
Cummings J; Reiber C; Kumar P
Alzheimers Dement (N Y); 2018; 4():330-343. PubMed ID: 30175227
[TBL] [Abstract][Full Text] [Related]
2. National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points.
Ghazarian AL; Haim T; Sauma S; Katiyar P
Alzheimers Dement; 2022 Feb; 18(2):348-359. PubMed ID: 34374496
[TBL] [Abstract][Full Text] [Related]
3. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
Chung TD
Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
[TBL] [Abstract][Full Text] [Related]
4. Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative.
Cummings JL; Ringman J; Metz K
J Alzheimers Dis; 2010; 19(2):375-88. PubMed ID: 20110588
[TBL] [Abstract][Full Text] [Related]
5. Advancing pediatric medical device development via non-dilutive NIH SBIR/STTR grant funding.
Sun RC; Kamat I; Byju AG; Wettergreen M; Heffernan MJ; Willson R; Haridas B; Koh CJ
J Pediatr Surg; 2021 Nov; 56(11):2118-2123. PubMed ID: 33558071
[TBL] [Abstract][Full Text] [Related]
6. Investor initiatives program: Public-private partnerships to expedite commercialization for NCI-funded small business entrepreneurs.
Connors B; Lou XJ; Subedee A; Zhang K; Weingarten M; Narayanan D
Clin Transl Sci; 2021 Nov; 14(6):2124-2131. PubMed ID: 34387931
[TBL] [Abstract][Full Text] [Related]
7. Foundation-industry relationships--a new business model joint-venture philanthropy in therapy development.
Bartek RJ
Curr Top Med Chem; 2014; 14(3):313-8. PubMed ID: 24283968
[TBL] [Abstract][Full Text] [Related]
8. Creative partnerships for funding nursing research.
McCann JJ; Hills EB; Zauszniewski JA; Smith CE; Farran CJ; Wilkie DJ
West J Nurs Res; 2011 Feb; 33(1):79-105. PubMed ID: 20719996
[TBL] [Abstract][Full Text] [Related]
9. Funding Research Through the Online Partnership to Accelerate Research (OnPAR).
Dueñas MA; Bisceglio I
JACC Basic Transl Sci; 2016 Oct; 1(6):536-540. PubMed ID: 30167536
[TBL] [Abstract][Full Text] [Related]
10. Who funds Alzheimer's disease drug development?
Cummings J; Bauzon J; Lee G
Alzheimers Dement (N Y); 2021; 7(1):e12185. PubMed ID: 34095442
[TBL] [Abstract][Full Text] [Related]
11. Geographically-related outcomes of U.S. funding for small business research and development: Results of the research grant programs of a component of the National Institutes of Health.
Onken J; Aragon R; Calcagno AM
Eval Program Plann; 2019 Dec; 77():101696. PubMed ID: 31404866
[TBL] [Abstract][Full Text] [Related]
12. An analysis of the NIH-supported sickle cell disease research portfolio.
Gavini N; Hoots WK; Mensah GA; Hanspal M
Blood Cells Mol Dis; 2015 Feb; 54(2):198-205. PubMed ID: 25466208
[TBL] [Abstract][Full Text] [Related]
13. National Heart, Lung, and Blood Institute and the translation of cardiovascular discoveries into therapeutic approaches.
Galis ZS; Black JB; Skarlatos SI
Circ Res; 2013 Apr; 112(9):1212-8. PubMed ID: 23620235
[TBL] [Abstract][Full Text] [Related]
14. Trends in Clinical Research Including Asian American, Native Hawaiian, and Pacific Islander Participants Funded by the US National Institutes of Health, 1992 to 2018.
Ðoàn LN; Takata Y; Sakuma KK; Irvin VL
JAMA Netw Open; 2019 Jul; 2(7):e197432. PubMed ID: 31339543
[TBL] [Abstract][Full Text] [Related]
15. Broadview Ventures: Investing in the Future of Cardiovascular Technology.
Colecchi C; Tancredi D
JACC Basic Transl Sci; 2016; 1(1-2):87-93. PubMed ID: 30167507
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of public and private funding in the medical device industry.
Kang HD; Edelman ER; Ku DN
Expert Rev Med Devices; 2018 Feb; 15(2):91-98. PubMed ID: 29256320
[TBL] [Abstract][Full Text] [Related]
17. Design of comprehensive Alzheimer's disease centers to address unmet national needs.
Trojanowski JQ; Arnold SE; Karlawish JH; Brunden K; Cary M; Davatzikos C; Detre J; Gaulton G; Grossman M; Hurtig H; Jedrziewski K; McCluskey L; Naylor M; Polsky D; Schellenberg GD; Siderowf A; Shaw LM; Van Deerlin V; Wang LS; Werner R; Xie SX; Lee VM
Alzheimers Dement; 2010 Mar; 6(2):150-5. PubMed ID: 20298979
[TBL] [Abstract][Full Text] [Related]
18. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide association study meta-analysis identifies three novel loci for circulating anti-Müllerian hormone levels in women.
Verdiesen RMG; van der Schouw YT; van Gils CH; Verschuren WMM; Broekmans FJM; Borges MC; Gonçalves Soares AL; Lawlor DA; Eliassen AH; Kraft P; Sandler DP; Harlow SD; Smith JA; Santoro N; Schoemaker MJ; Swerdlow AJ; Murray A; Ruth KS; Onland-Moret NC
Hum Reprod; 2022 May; 37(5):1069-1082. PubMed ID: 35274129
[TBL] [Abstract][Full Text] [Related]
20. Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry.
Zhou EW; Jackson MJ; Ledley FD
JAMA Health Forum; 2023 Jul; 4(7):e231921. PubMed ID: 37450296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
